

**To:** (10)(2e) [redacted] @epiconcept.fr  
**Cc:** (10)(2e) [redacted] @rivm.nl]; (10)(2e) [redacted] @rivm.nl]; (10)(2e) [redacted] @nivel.nl];  
(10)(2e) [redacted] @nivel.nl]; (10)(2e) [redacted] @rivm.nl]  
**From:** (10)(2e) [redacted] @rivm.nl]  
**Sent:** Tue 11/3/2020 2:28:52 PM  
**Subject:** RE: I-MOVE influenza primary care: ESCAIDE presentation + next season deliverables  
**Received:** Tue 11/3/2020 2:28:54 PM  
[Annex 1 118638\\_011100\\_IDS\\_formulier\\_NIVEL\\_aangepast\\_CONCEPT.pdf](#)  
[Annex 2 P1. Advies onderzoek \(niet-\)WMO 15-389 dd 05-08-2015.docx.pdf](#)  
[2020\\_11\\_03\\_Country\\_specific\\_annex\\_I-MOVE\\_case\\_control\\_study\\_the\\_Netherlands\\_2020-2021\\_for\\_ECDC\\_and\\_Epiconcept.pdf](#)

Dear (10)(2e) [redacted]

Please find attached our country specific protocol for our participation in I-MOVE influenza for the season 2020-2021 and the 2 annexes. Please note that the sample form (annex 1) is not definitive yet as we are currently working on finalizing the last minor points and layout etc. We can send you the definite version later. All the differences compared to previous season that are due to COVID-19 are marked in blue.

If you have any questions, please let us know!

Kind regards,

(10)(2e) [redacted]  
(10)(2e) [redacted]

RIVM - Centrum Infectieziekten Epidemiologie & Surveillanc  
Postbus 1 (interne postbak) [redacted]  
3720 BA Bilthoven [redacted]  
Tel. 030 - (10)(2e) [redacted]  
Werkdagen: (10)(2e) [redacted]

RIVM, National Institute for Public Health and the Environment  
PO Box 1  
3720 BA Bilthoven  
The Netherlands

**From:** (10)(2e) [redacted] <(10)(2e) [redacted]@epiconcept.fr>

**Sent:** dinsdag 20 oktober 2020 10:01

**To:** (10)(2e) [redacted] @epiconcept.fr; (10)(2e) [redacted] @epiconcept.fr; (10)(2e) [redacted] @isciii.es; (10)(2e) [redacted] @isciii.es; (10)(2e) [redacted] @santepubliquefrance.fr; (10)(2e) [redacted] @hzjz.hr; (10)(2e) [redacted] @rki.de; (10)(2e) [redacted] @rki.de; (10)(2e) [redacted] @pasteur.fr;  
(10)(2e) [redacted] @univ-corse.fr; (10)(2e) [redacted] @iplesp.upmc.fr; (10)(2e) [redacted] @hzjz.hr; (10)(2e) [redacted] @hzjz.hr; (10)(2e) [redacted] @hzjz.hr; (10)(2e) [redacted] @folkhalsomyndigheten.se; (10)(2e) [redacted] @rivm.nl>; (10)(2e) [redacted] @rivm.nl>; (10)(2e) [redacted] @rivm.nl>; (10)(2e) [redacted] @hse.ie; (10)(2e) [redacted] @hse.ie; (10)(2e) [redacted] @cantacuzino.ro; (10)(2e) [redacted] @insa.min-saude.pt; (10)(2e) [redacted] @insa.min-saude.pt; (10)(2e) [redacted] @insa.min-saude.pt; (10)(2e) [redacted] @insa.min-saude.pt; (10)(2e) [redacted] @rki.de; (10)(2e) [redacted] @santepubliquefrance.fr; (10)(2e) [redacted] @rki.de; (10)(2e) [redacted] @navarra.es; (10)(2e) [redacted] @pasteur.fr; (10)(2e) [redacted] @upmc.fr; (10)(2e) [redacted] @isciii.es; (10)(2e) [redacted] @cfnavarra.es; (10)(2e) [redacted] @pasteur.fr; (10)(2e) [redacted] @insa.min-saude.pt; (10)(2e) [redacted] @rki.de; (10)(2e) [redacted] @iplesp.upmc.fr; (10)(2e) [redacted] @folkhalsomyndigheten.se; (10)(2e) [redacted] @nivel.nl; (10)(2e) [redacted] @yahoo.com; (10)(2e) [redacted] @hpsec.ie; Linda <(10)(2e) [redacted]@ucd.ie>; (10)(2e) [redacted] @ucd.ie; (10)(2e) [redacted] @rivm.nl> <(10)(2e) [redacted]@rivm.nl>  
**Cc:** (10)(2e) [redacted] @epiconcept.fr; (10)(2e) [redacted] <(10)(2e) [redacted]@ecd.europa.eu>; (10)(2e) [redacted] <(10)(2e) [redacted]@ecd.europa.eu>

**Subject:** I-MOVE influenza primary care: ESCAIDE presentation + next season deliverables

Dear all,

I hope you are well.

We are pleased to inform you that our **abstract for ESCAIDE** on the 2019–20 I-MOVE primary care multicentre study was accepted for a pre-recorded presentation and live Q&A (see email below). Thank you to all, and hopefully we will see each other online at the Q&A session.

As you know, we have received a new contract from ECDC for the **2020–21 influenza season**. We would like to have a

**kick-off meeting** for this in November. Please could you indicate your availability here:  
<https://doodle.com/poll/saehxyfb7zilhwigf>

And just as a reminder about the **2020-21 study-site specific protocols** - I am copying here Marta's last email:  
*Valérie will prepare the 2020/21 contract. We should submit to ECDC the site protocols by 15 November. Therefore, please send them to us by 2nd November if possible.*

We know you are very busy, so if you need more time for the protocols, please let us know. In the protocols, could you **highlight any changes compared to the 2019-20 season that are due to COVID-19?**

Please do not hesitate to get in touch with us if you have any questions or concerns.  
 Wishing you all the best,

(10)(2e) and the I-MOVE team.

----- Forwarded Message -----

**Subject:**ESCAIDE 2020 - abstract submission result

**Date:**Fri, 16 Oct 2020 17:11:41 +0200 (CEST)

**From:**ESCAIDE <(10)(2e)@escaideconference.eu>

**To:** (10)(2e)@epiconcept.fr



Dear (10)(2e)

**Abstract Title:** Vaccine effectiveness against influenza A(H1N1)pdm09, A(H3N2) and B: Results from the 2019/20 European I-MOVE primary care multicentre study

**Abstract ID:** 115

We are very pleased to let you know that your abstract has been selected for a **pre-recorded presentation with a live Question & Answer session** at the European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE), to be held online between 24 and 27 November 2020. Congratulations on this opportunity to showcase your work.

Should you be interested in comments regarding your abstract, please see below. Note that not all reviewers give comments, hence, it may be that no comments are available for your abstract.

All abstracts have been independently reviewed by three experts using the ESCAIDE [reviewers' guidelines](#). The ESCAIDE [selection guidelines](#) have then been applied to decide which abstracts select for ESCAIDE 2020. The process has been overseen by the ESCAIDE Scientific Committee.

#### CONFERENCE REGISTRATION

Please note that registration for the Conference will open on 2 November. The registration is free of charge and compulsory for all those who would like to join the Conference, regular participants and speakers as well. More information on the registration can be found on our website [www.escaide.eu](http://www.escaide.eu)

#### CONFERENCE PROGRAMME

The provisional programme is available on the Conference website and is updated regularly. Please check the website for the latest updates, including the date and time allocated to your presentation.

#### GUIDELINES FOR PRE-RECORDED PRESENTATIONS

Full guidelines for presenters are available on our [website](#).

Please make sure you consult all the guides as they contain pertinent information on how your presentation will be delivered as a pre-recorded presentation, with a live connection for the Q&A session.

You will also find information on the different functionalities of the platform used to deliver ESCAIDE 2020 in an online format (Swapcard).

**ABSTRACT COPYRIGHT CONSENT**

Please note that all accepted abstracts at ESCAIDE 2020 are made available on the conference platform (Swapcard) and in ESCAIDE's abstract book so that ESCAIDE participants can share your experience and benefit from your work. You can see the abstract books from the [past ESCAIDE](#) on the Conference website.

**YOUR CONTACT DETAILS**

Your/the presenting author's contact email address will be added in this year's abstract book and also made available on the conference platform (Swapcard). The rationale is to give the attendees possibilities to interact outside of the Q&A sessions and network.

**We note that you have consented to this and assume that all other co-authors have also given their consent.**

**CONFIRMATION**

Please inform us if you will not be able to present OR if there is a change in the presenter of your abstract, by latest 22 October 2020, at [\(10\)\(2e\)@ecdc.europa.eu](#)

Please do not hesitate to contact us if you have any questions.

With best regards,  
ESCAIDE Organising Team

**ABSTRACT RESULTS**

The following reviewers' comments are available for your abstract:

**REVIEWERS COMMENTS**

(10)(2g)